Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes.

Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, Rothman RB.

Psychopharmacology (Berl). 2019 Mar;236(3):915-924. doi: 10.1007/s00213-018-5063-9. Epub 2018 Oct 20.

PMID:
30341459
2.

Cocaine-like discriminative stimulus effects of "norepinephrine-preferring" monoamine releasers: time course and interaction studies in rhesus monkeys.

Kohut SJ, Jacobs DS, Rothman RB, Partilla JS, Bergman J, Blough BE.

Psychopharmacology (Berl). 2017 Dec;234(23-24):3455-3465. doi: 10.1007/s00213-017-4731-5. Epub 2017 Sep 9.

3.
4.

Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.

Rothman RB, Ananthan S, Partilla JS, Saini SK, Moukha-Chafiq O, Pathak V, Baumann MH.

J Pharmacol Exp Ther. 2015 Jun;353(3):529-38. doi: 10.1124/jpet.114.222299. Epub 2015 Mar 18.

5.

Association of subarachnoid hemorrhage and phentermine usage: Coincidence, not causation.

Hendricks EJ, Rothman RB, Bryman DA, Schmidt SL.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):122, 124. doi: 10.1331/JAPhA.2015.14263. No abstract available.

PMID:
25616199
6.

Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.

Iyer MR, Rothman RB, Dersch CM, Jacobson AE, Rice KC.

Eur J Med Chem. 2015 Mar 6;92:531-9. doi: 10.1016/j.ejmech.2015.01.025. Epub 2015 Jan 13.

7.

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL.

Drug Alcohol Depend. 2015 Feb 1;147:1-19. doi: 10.1016/j.drugalcdep.2014.12.005. Epub 2014 Dec 18. Review.

8.

Alpha-ethyltryptamines as dual dopamine-serotonin releasers.

Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB.

Bioorg Med Chem Lett. 2014 Oct 1;24(19):4754-4758. doi: 10.1016/j.bmcl.2014.07.062. Epub 2014 Jul 29.

9.

Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.

Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, Rothman RB.

ACS Med Chem Lett. 2014 Apr 15;5(6):623-7. doi: 10.1021/ml500113s. eCollection 2014 Jun 12.

10.

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB.

Psychopharmacology (Berl). 2014 Oct;231(21):4135-44. doi: 10.1007/s00213-014-3557-7. Epub 2014 May 7.

11.

Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.

Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, Negus SS.

Exp Clin Psychopharmacol. 2014 Jun;22(3):274-284. doi: 10.1037/a0036595. Epub 2014 May 5.

12.

Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates.

Baumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS, Ali SF, Stockner T, Rothman RB, Sandtner W, Sitte HH.

Neuropsychopharmacology. 2014 May;39(6):1355-65. doi: 10.1038/npp.2013.331. Epub 2013 Nov 28.

13.

Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.

PLoS One. 2013 Oct 16;8(10):e77262. doi: 10.1371/journal.pone.0077262. eCollection 2013.

14.

Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA.

Drug Metab Dispos. 2014 Jan;42(1):119-25. doi: 10.1124/dmd.113.053678. Epub 2013 Oct 18.

15.

Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.

Lim HJ, Dersch CM, Rothman RB, Deschamps JR, Jacobson AE, Rice KC.

Eur J Med Chem. 2013 Sep;67:335-43. doi: 10.1016/j.ejmech.2013.06.030. Epub 2013 Jun 25.

16.

Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys.

Kohut SJ, Fivel PA, Blough BE, Rothman RB, Mello NK.

Int J Neuropsychopharmacol. 2013 Oct;16(9):1985-98. doi: 10.1017/S146114571300059X. Epub 2013 Jun 17.

PMID:
23768644
17.

Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.

Iyer MR, Rothman RB, Dersch CM, Jacobson AE, Rice KC.

Bioorg Med Chem. 2013 Jun 1;21(11):3298-309. doi: 10.1016/j.bmc.2013.02.060. Epub 2013 Apr 3.

18.

Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.

Schmitt KC, Rothman RB, Reith ME.

J Pharmacol Exp Ther. 2013 Jul;346(1):2-10. doi: 10.1124/jpet.111.191056. Epub 2013 Apr 8. Review.

19.

Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.

Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH.

Eur J Pharmacol. 2013 Jan 15;699(1-3):180-7. doi: 10.1016/j.ejphar.2012.11.008. Epub 2012 Nov 21.

20.

Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans.

Li F, Deck JA, Dersch CM, Rothman RB, Deschamps JR, Jacobson AE, Rice KC.

Eur J Med Chem. 2012 Dec;58:557-67. doi: 10.1016/j.ejmech.2012.10.041. Epub 2012 Oct 30.

21.

Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW.

Neuropsychopharmacology. 2013 Mar;38(4):552-62. doi: 10.1038/npp.2012.204. Epub 2012 Oct 17.

22.

Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters.

Severinsen K, Kraft JF, Koldsø H, Vinberg KA, Rothman RB, Partilla JS, Wiborg O, Blough B, Schiøtt B, Sinning S.

ACS Chem Neurosci. 2012 Sep 19;3(9):693-705. Epub 2012 Jun 10.

23.

14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.

Ananthan S, Saini SK, Dersch CM, Xu H, McGlinchey N, Giuvelis D, Bilsky EJ, Rothman RB.

J Med Chem. 2012 Oct 11;55(19):8350-63. doi: 10.1021/jm300686p. Epub 2012 Sep 27.

24.

An efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist.

Martin DJ, FitzMorris PE, Li B, Ayestas M, Sally EJ, Dersch CM, Rothman RB, Deveau AM.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6801-5. doi: 10.1016/j.bmcl.2012.06.056. Epub 2012 Jun 23.

PMID:
22771010
25.

Semisynthetic neoclerodanes as kappa opioid receptor probes.

Lovell KM, Vasiljevik T, Araya JJ, Lozama A, Prevatt-Smith KM, Day VW, Dersch CM, Rothman RB, Butelman ER, Kreek MJ, Prisinzano TE.

Bioorg Med Chem. 2012 May 1;20(9):3100-10. doi: 10.1016/j.bmc.2012.02.040. Epub 2012 Mar 1.

26.

Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

Prevatt-Smith KM, Lovell KM, Simpson DS, Day VW, Douglas JT, Bosch P, Dersch CM, Rothman RB, Kivell B, Prisinzano TE.

Medchemcomm. 2011 Dec;2(12):1217-1222.

27.

Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.

Iyer MR, Lee YS, Deschamps JR, Dersch CM, Rothman RB, Jacobson AE, Rice KC.

Eur J Med Chem. 2012 Apr;50:44-54. doi: 10.1016/j.ejmech.2012.01.025. Epub 2012 Jan 20.

28.

Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE.

J Pharmacol Exp Ther. 2012 Apr;341(1):251-62. doi: 10.1124/jpet.111.188946. Epub 2012 Jan 23.

29.

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV.

Neuropsychopharmacology. 2012 Apr;37(5):1192-203. doi: 10.1038/npp.2011.304. Epub 2011 Dec 14.

30.

Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Yubero-Lahoz S, Ayestas MA Jr, Blough BE, Partilla JS, Rothman RB, de la Torre R, Baumann MH.

Eur J Pharmacol. 2012 Jan 15;674(2-3):337-44. doi: 10.1016/j.ejphar.2011.10.033. Epub 2011 Nov 3.

31.

Phentermine therapy for obesity does not elevate blood pressure.

Hendricks EJ, Rothman RB.

Diabetes Obes Metab. 2011 Oct;13(10):963-4. doi: 10.1111/j.1463-1326.2011.01435.x. No abstract available.

PMID:
21896124
32.

RE: Pulmonary hypertension associated with use of phentermine?

Hendricks EJ, Rothman RB.

Yonsei Med J. 2011 Sep;52(5):869-70. doi: 10.3349/ymj.2011.52.5.869. No abstract available.

33.

Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: compounds with moderate to low opioid-receptor affinity.

Li F, Folk JE, Cheng K, Kurimura M, Deck JA, Deschamps JR, Rothman RB, Dersch CM, Jacobson AE, Rice KC.

Bioorg Med Chem. 2011 Jul 15;19(14):4330-7. doi: 10.1016/j.bmc.2011.05.035. Epub 2011 May 24.

34.

Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.

Kim JH, Deschamps JR, Rothman RB, Dersch CM, Folk JE, Cheng K, Jacobson AE, Rice KC.

Bioorg Med Chem. 2011 Jun 1;19(11):3434-43. doi: 10.1016/j.bmc.2011.04.028. Epub 2011 Apr 22.

35.

Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension.

Rothman RB, Cadet JL, Dersch CM, McCoy MT, Lehrmann E, Becker KG, Bader M, Alenina N, Baumann MH.

PLoS One. 2011 Mar 25;6(3):e17735. doi: 10.1371/journal.pone.0017735.

36.

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Cunningham CW, Rothman RB, Prisinzano TE.

Pharmacol Rev. 2011 Jun;63(2):316-47. doi: 10.1124/pr.110.003244. Epub 2011 Mar 28. Review.

37.

Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.

Lozama A, Cunningham CW, Caspers MJ, Douglas JT, Dersch CM, Rothman RB, Prisinzano TE.

J Nat Prod. 2011 Apr 25;74(4):718-26. doi: 10.1021/np1007872. Epub 2011 Feb 21.

38.

Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats.

Clifford PS, Hart N, Rothman RB, Blough BE, Bratton GR, Wellman PJ.

Life Sci. 2011 Mar 28;88(13-14):586-9. doi: 10.1016/j.lfs.2011.01.007. Epub 2011 Jan 21.

39.

Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans.

Cheng K, Lee YS, Rothman RB, Dersch CM, Bittman RW, Jacobson AE, Rice KC.

J Med Chem. 2011 Feb 24;54(4):957-69. doi: 10.1021/jm1011676. Epub 2011 Jan 19.

40.

In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat.

Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB.

J Pharmacol Exp Ther. 2011 Apr;337(1):218-25. doi: 10.1124/jpet.110.176271. Epub 2011 Jan 12.

41.

Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat.

Baumann MH, Williams Z, Zolkowska D, Rothman RB.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):147-52. doi: 10.1016/j.drugalcdep.2010.09.015. Epub 2010 Nov 10.

42.

In vitro and in vivo assessment of mu opioid receptor constitutive activity.

Bilsky EJ, Giuvelis D, Osborn MD, Dersch CM, Xu H, Rothman RB.

Methods Enzymol. 2010;484:413-43. doi: 10.1016/B978-0-12-381298-8.00021-6.

PMID:
21036244
43.

Evidence for noncompetitive modulation of substrate-induced serotonin release.

Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, Partilla JS.

Synapse. 2010 Nov;64(11):862-9. doi: 10.1002/syn.20804.

44.

Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19.

Rothman RB, Hendricks EJ.

Int J Cardiol. 2010 Nov 19;145(2):391-392. doi: 10.1016/j.ijcard.2010.02.060. Epub 2010 Mar 6.

PMID:
20207432
45.

Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.

Hsin LW, Chang LT, Rothman RB, Dersch CM, Fishback JA, Matsumoto RR.

J Med Chem. 2010 Feb 11;53(3):1392-6. doi: 10.1021/jm901503e.

PMID:
20055417
46.

Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity.

Fontana G, Savona G, Rodríguez B, Dersch CM, Rothman RB, Prisinzano TE.

Tetrahedron. 2008 Dec 20;64(43):10041-10048.

47.

Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols.

Iyer MR, Lee YS, Deschamps JR, Rothman RB, Dersch CM, Jacobson AE, Rice KC.

Bioorg Med Chem. 2010 Jan 1;18(1):91-9. doi: 10.1016/j.bmc.2009.11.022. Epub 2009 Nov 18.

48.

Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.

Sally EJ, Xu H, Dersch CM, Hsin LW, Chang LT, Prisinzano TE, Simpson DS, Giuvelis D, Rice KC, Jacobson AE, Cheng K, Bilsky EJ, Rothman RB.

Synapse. 2010 Apr;64(4):280-8. doi: 10.1002/syn.20723.

49.

Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Baumann MH, Rothman RB.

Int Rev Neurobiol. 2009;88:257-96. doi: 10.1016/S0074-7742(09)88010-0.

50.

Phentermine cardiovascular safety.

Rothman RB, Hendricks EJ.

Am J Emerg Med. 2009 Oct;27(8):1010-3. doi: 10.1016/j.ajem.2009.07.014. No abstract available.

PMID:
19857423

Supplemental Content

Loading ...
Support Center